Gene test to predict early treatment failure in follicular lymphoma
Official title: Assay Development and Prognostic Model for Predicting Early Clinical Failure in Follicular Lymphoma
Funded at University of Arizona · NIH-11195009 · Data updated 2026-11-12
A lab test that reads genes in lymphoma biopsy tissue to spot people with follicular lymphoma who are likely to have their disease return within two years after standard immunochemotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | September 19, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $161,663 |
| NIH project number | 5UH2CA292129-02 |
| Project ID | NIH-11195009 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people with newly diagnosed or recently treated follicular lymphoma who have available tumor biopsy tissue (FFPET) from diagnosis or treatment.
✕Less likely to help
Patients without available biopsy tissue, those with non-follicular lymphomas, or people already more than two years past treatment are unlikely to benefit directly from this project.
What this research studies
You would be asked to let researchers use routine biopsy tissue (formalin-fixed, paraffin-embedded) from your lymphoma to run a gene-expression test called FL24Cx on the NanoString nCounter platform. In the first phase they will refine and standardize the assay for clinical-grade use, and in the second phase they will validate how well the test predicts early clinical failure (failing to remain event-free at 24 months after treatment). The team will compare test results against known outcomes from treated patients, using archived and prospectively collected samples to measure accuracy. The goal is a reliable test that can be run on usual pathology specimens so results could be used in real clinical care.
Why it matters
Potential benefit: If successful, the test could help doctors identify high-risk follicular lymphoma patients at diagnosis so treatment can be tailored earlier.
How similar studies have gone: The team has an internally validated gene-expression signature and similar NanoString-based prognostic tests in other cancers have shown promise but require external validation.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: Rimsza, Lisa — University of Arizona
- Study coordinator: Rimsza, Lisa
Related research
Other NIH-funded projects on the same topics.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Follicular Lymphoma: Better Diagnosis and Personalized Risk in B-Cell Lymphomas
This NIH grant aims to improve how doctors diagnose and predict outcomes for people with follicular lymphoma by finding reliable biomarkers to guide treatment decisions.
-
IRF4's role in shaping the tumor environment in follicular lymphoma
This grant aims to understand how a molecule called IRF4 changes the tumor surroundings in follicular lymphoma to identify potential new ways to help patients.
-
How mutant STAT6 affects follicular lymphoma
This project looks at how a gene change called STAT6 affects follicular lymphoma to help find better treatments for people with this cancer.
-
Preventing the progression of follicular lymphoma with targeted therapy
This study is looking at how slow-growing follicular lymphomas can change into more aggressive forms, and it's working to find personalized treatments that target the specific factors that help these tumors survive, so we can help patients live better and longer.
-
Developing a test to predict early treatment failure in follicular lymphoma
This study is looking to help doctors better predict which patients with follicular lymphoma might not respond well to standard treatment, using a special test on tissue samples to find important genetic clues, so they can create more personalized treatment plans for you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.